Sputum test for lung cancer nears approval in Canada and Europe
This article was originally published in Clinica
A sputum test for lung cancer in high-risk patients could receive regulatory approval from Canadian authorities as early as spring 2006. The ClearSign test, developed by Perceptronix, uses AQC (automated qualitative cytometry) technology. The Vancouver, Canada-based company is also using the same technology to develop a lung cancer screening test based on buccal samples (cheek scrapings).
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.